## Amendments to the Claims:

1. (Currently Amended) A double-stranded RNA which is composed of sense- and antisense-strand RNAs, homologous to a certain sequence composed of base sequences shown in SEQ ID NOs: 3 and 4 in the sequence listing targeted against a huntingtin mRNA, wherein the double-stranded RNA which can inhibit huntingtin gene expression.

## 2-6. (Cancelled)

- 7. (Currently Amended) The double-stranded RNA according to claim 1 any one of <del>claims 1 to 6</del> prepared from synthesized sense- and antisense-strand RNAs.
- 8. (Currently Amended) The double-stranded RNA according to claim 1 any one of claims 1 to 6, which is prepared from sense- and antisense-strand RNAs generated by using gene recombination.
- 9. (Original) The double-stranded RNA according to claim 8, wherein the sense- and antisense-strand RNAs generated by using gene recombination are prepared by obtaining RNAs which are generated by introducing a expression vector incorporated DNA capable of transcribing respectively the RNAs, into a host cell.
- 10. (Currently Amended) A huntingtin gene expression inhibitor composed of the doublestranded RNA according to any one of claims 1, and 7 to 9.
- 11. (Currently Amended) A huntingtin gene expression inhibitor composed of a fusion product, wherein the double-stranded RNA according to any one of claims 1, and 7 to 9 is added to a TAT sequence, a protein transduction domain derived from HIV-1.
- 12. (Currently Amended) A huntingtin gene expression inhibitor composed of a complex formed from the double-stranded RNA according to any one of claims 1, and 7 to 9 and a

Appl. No.: 10/556,711

Amdt. Dated April 20, 2009

Reply to Office Action of 11/28/2008 and Notice of Non-Compliant Amendment of 4/10/2009

positively-charged ribosome/lipid.

13. (Currently Amended) A huntingtin gene expression inhibitor composed of an expression vector incorporating a DNA capable of transcribing the double-stranded RNA according to <u>claim 1</u> any one of claims 1 to 6.

- 14. (Withdrawn) A method for suppressing the expression of a huntingtin gene in a living body or living cell of a mammal, said method comprising introducing into a living body or living cell of a mammal a huntingtin gene expression inhibitor selected from the group consisting of:
- a. a huntingtin gene expression inhibitor composed of a double-stranded RNA composed of sense- and antisense-strand RNAs, homologous to a certain sequence targeted against a huntingtin mRNA;
- b. a huntingtin gene expression inhibitor composed of a fusion product, wherein a double-stranded RNA composed of sense- and antisense-strand RNAs, homologous to a certain sequence targeted against a huntingtin mRNA is added to a TAT sequence, a protein transduction domain derived from HIV-1;
- c. a huntingtin gene expression inhibitor composed of a complex formed from a double-stranded RNA composed of sense- and antisense-strand RNAs, homologous to a certain sequence targeted against a huntingtin mRNA and a positively-charged ribosome/lipid; and
- d. a huntingtin gene expression inhibitor composed of an expression vector incorporating a DNA capable of transcribing a double-stranded RNA composed of sense- and antisense-strand RNAs, homologous to a certain sequence targeted against a huntingtin mRNA.
- 15. (Original) A preventive and/or a remedy of Huntington's disease containing the huntingtin gene expression inhibitor according to any one of claims 10 to 13 as an effective ingredient.

Appl. No.: 10/556,711

Amdt. Dated April 20, 2009

Reply to Office Action of 11/28/2008 and Notice of Non-Compliant Amendment of 4/10/2009

16. (Original) The preventive and/or the remedy of Huntington's disease according to claim 15 further containing a pharmaceutically acceptable carrier.

17. (Withdrawn) A method for preventing the development and/or treatment for Huntington's disease, wherein the preventive and/or the remedy of Huntington's disease of claim 15 is introduced into a living body or living cell of a mammal.